Author:
Wu Junqing,Xiao Yanyu,Sun Jie,Sun Huiyu,Chen Haide,Zhu Yuanyuan,Fu Huarui,Yu Chengxuan,E. Weigao,Lai Shujing,Ma Lifeng,Li Jiaqi,Fei Lijiang,Jiang Mengmeng,Wang Jingjing,Ye Fang,Wang Renying,Zhou Ziming,Zhang Guodong,Zhang Tingyue,Ding Qiong,Wang Zou,Hao Sheng,Liu Lizhen,Zheng Weiyan,He Jingsong,Huang Weijia,Wang Yungui,Xie Jin,Li Tiefeng,Cheng Tao,Han Xiaoping,Huang He,Guo Guoji
Abstract
Abstract
Background
Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy and has a prognosis that varies with its genetic complexity. However, there has been no appropriate integrative analysis on the hierarchy of different AML subtypes.
Methods
Using Microwell-seq, a high-throughput single-cell mRNA sequencing platform, we analyzed the cellular hierarchy of bone marrow samples from 40 patients and 3 healthy donors. We also used single-cell single-molecule real-time (SMRT) sequencing to investigate the clonal heterogeneity of AML cells.
Results
From the integrative analysis of 191727 AML cells, we established a single-cell AML landscape and identified an AML progenitor cell cluster with novel AML markers. Patients with ribosomal protein high progenitor cells had a low remission rate. We deduced two types of AML with diverse clinical outcomes. We traced mitochondrial mutations in the AML landscape by combining Microwell-seq with SMRT sequencing. We propose the existence of a phenotypic “cancer attractor” that might help to define a common phenotype for AML progenitor cells. Finally, we explored the potential drug targets by making comparisons between the AML landscape and the Human Cell Landscape.
Conclusions
We identified a key AML progenitor cell cluster. A high ribosomal protein gene level indicates the poor prognosis. We deduced two types of AML and explored the potential drug targets. Our results suggest the existence of a cancer attractor.
Funder
National Key Research and Development Program
National Natural Science Foundation of China
Zhejiang Provincial Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology